Filtros de búsqueda

Lista de obras de Fabio Stagno

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line

artículo científico publicado en 2016

Aberrant phenotypic expression of the T-cell-associated antigen CD8 on B-cell chronic lymphocytic leukemia cells

artículo científico publicado en 2009

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

artículo científico publicado en 2015

Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study

artículo científico publicado en 2015

Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

All-trans-retinoic-acid- and growth-factor- mediated induction of alkaline phosphatase activity in freshly isolated chronic myeloid leukemia cells

scientific article published on 01 January 1999

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart

scientific article published on 17 April 2019

B-ALL Relapses After Autologous Stem Cell Transplantation Associated With a Shift from e1a2 to e14a2 BCR-ABL Transcripts: A Case Report

artículo científico publicado en 2019

BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B.

artículo científico publicado en 2005

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors

artículo científico publicado en 2019

BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint.

artículo científico publicado en 2011

CD34 expression in adult acute lymphoblastic leukemia

scientific article published on 01 January 1995

Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.

artículo científico publicado en 2018

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

artículo científico publicado en 2011

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53

artículo científico publicado en 2019

Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib

artículo científico publicado en 2013

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey

scientific article published on 18 June 2020

Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib. ⬇️

artículo científico publicado en 2019

Clinical relevance of the association of interferon alfa to imatinib in chronic myeloid leukemia therapy

artículo científico publicado en 2012

Colony-Forming Cell Assay Detecting the Co-Expression of JAK2V617F and BCR-ABL1 in the Same Clone: A Case Report

scientific article published on 09 April 2019

Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias.

artículo científico publicado en 2010

Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy

artículo científico publicado en 2010

Dasatinib first-line: Multicentric Italian experience outside clinical trials

artículo científico publicado en 2015

Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

scientific article published on 25 June 2011

Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients

artículo científico publicado en 2010

Diagnosis of blastic phase of chronic myeloid leukemia

scientific article published on 21 March 2012

Differences among young adults, adults and elderly chronic myeloid leukemia patients.

artículo científico publicado en 2014

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation

artículo científico publicado en 2019

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

artículo científico publicado en 2013

Effects of imatinib mesylate in osteoblastogenesis

artículo científico publicado en 2009

Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors

artículo científico publicado en 2011

Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report

scientific article published on 01 July 2019

Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22)

artículo científico publicado en 2019

Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis.

artículo científico publicado en 2001

Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques

artículo científico publicado en 2015

Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.

artículo científico publicado en 2004

Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

artículo científico publicado en 2016

Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors

artículo científico publicado en 2011

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.

artículo científico publicado en 2018

Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy

scientific article published on 02 September 2019

High BCR-ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib

artículo científico publicado en 2017

Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia

scientific article published on 05 October 2011

Hypereosinophilia and subcutaneous heparin

artículo científico publicado en 1993

IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.

artículo científico publicado en 2014

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

artículo científico publicado en 2016

Imatinib discontinuation: realistic for patients with chronic myeloid leukaemia achieving complete molecular remission? ⬇️

artículo científico publicado el 1 de febrero de 2011

Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up

artículo científico publicado en 2010

Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase

artículo científico publicado en 2008

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study

artículo científico publicado en 2013

Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.

artículo científico publicado en 2011

Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.

artículo científico publicado en 2016

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

artículo científico publicado en 2012

In vitro apoptotic response of freshly isolated chronic myeloid leukemia cells to all-trans retinoic acid and cytosine arabinoside

artículo científico publicado en 2000

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia

artículo científico publicado en 2017

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia

artículo científico publicado en 2012

Increased phospho-mTOR expression in megakaryocytic cells derived from CD34+ progenitors of essential thrombocythaemia and myelofibrosis patients.

artículo científico publicado en 2012

Infliximab therapy in hematologic malignancies: handle with care.

artículo científico publicado en 2012

Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

artículo científico publicado en 2010

Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era

scientific article published on 01 February 2014

Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors

scientific article published on 24 October 2019

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

artículo científico publicado en 2015

Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.

artículo científico publicado en 2015

Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study

artículo científico publicado en 2020

Management of Chronic Myeloid Leukemia in Advanced Phase

artículo científico publicado en 2019

Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment

artículo científico publicado en 2015

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP

artículo científico publicado en 2019

Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients

artículo científico publicado en 2016

Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib

artículo científico publicado en 2017

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

artículo científico publicado en 2011

Multidrug resistance mechanisms in chronic lymphocytic leukaemia

artículo científico publicado en 2002

Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.

artículo científico publicado en 2014

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper

scientific article published on 05 December 2019

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

artículo científico

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

artículo científico publicado en 2009

Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia

artículo científico publicado en 2018

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice

scientific article published on 28 February 2019

On the road to treatment-free remission in chronic myeloid leukemia: what about "the others"?

scientific article published on 26 September 2020

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

artículo científico publicado en 2012

Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline

scientific article published on 07 August 2019

Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment.

artículo científico publicado en 2012

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

artículo científico publicado en 2017

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

artículo científico publicado en 2020

Rapid decline of Philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report

artículo científico publicado en 2019

Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention

scientific article published on 17 April 2019

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

artículo científico publicado en 2009

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia

artículo científico publicado en 2016

SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub.

artículo científico publicado en 2018

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation

artículo científico publicado en 2013

Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis

artículo científico publicado en 2007

Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib

scientific article published on 01 September 2019

Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain.

artículo científico publicado en 2009

Successful treatment of advanced idiopathic myelofibrosis with imatinib mesylate

artículo científico publicado en 2004

Successful treatment of granulocytic sarcoma with alpha-interferon and disodium pamidronate at presentation of chronic myeloid leukemia

artículo científico publicado en 2001

Survivin expression in chronic myeloid leukemia

scientific article published on 07 December 2004

T cell receptor delta-chain gene rearrangement in a novel case of adult NK cell leukemia

scientific article published on 01 January 2004

The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias ⬇️

scientific article published on 04 December 2019

The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia

artículo científico publicado en 2015

The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up

artículo científico publicado en 2009

Towards a need to a "biological Sokal risk" in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia

scientific article published on 12 April 2012

Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia.

artículo científico publicado en 2010

Utility of flow cytometry as a screening tool for transplant donors for chronic lymphocytic leukemia

artículo científico publicado en 2010

VLA-2 and VLA-5 cell adhesion molecules expression in CD34+ cells from umbilical cord blood and from bone marrow

artículo científico publicado en 2002

Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia

artículo científico publicado en 2020

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda